Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel Bozsing is active.

Publication


Featured researches published by Daniel Bozsing.


European Journal of Medicinal Chemistry | 1996

Synthesis and pharmacological study of new 3,4-dihydro-2H,6H-pyrimido-[2,1-b][1,3]thiazines

Daniel Bozsing; Pál Sohár; Gabor Gigler; Gabor Kovacs

Summary A series of racemic pyrimido-thiazine derivatives was synthesized and many of their in vivo activities found to be comparable to acetylsalicylic acid and aminophenazone in an antiinflammatory model and an antipyretic test. Analogues 7a and 7e are the most potent in rat carrageenin and yeast fever assays. These compounds did not inhibit prostaglandin biosynthesis in vitro.


Cardiovascular Drugs and Therapy | 2003

Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist.

Anikó Kovács; Istvan Gacsalyi; Janos Wellmann; Eva Schmidt; Zsuzsanna Szücs; Valérie Dubreuil; Jean Paul Nicolas; Jean A. Boutin; Daniel Bozsing; Andras Egyed; Kasoly Tihanyi; Michael Spedding; Gábor Szénási

Our aim was to specify the 5-HT2 subtype selectivity of EGIS-7625 (1-benzyl-4-[(2-nitro-4-methyl-5-amino)-phenyl]-piperazine), a new 5-HT2B ligand, in receptor binding studies and characterize its pharmacology at 5-HT2A, 5-HT2B and 5-HT2C receptors in in vivo experiments and in isolated organs, in vitro. EGIS-7625 had high affinity for recombinant human 5-HT2B receptors (pKi = 9.0) but much weaker affinity for 5-HT2A and 5-HT2C receptors (pKi = 6.2 and 7.7, respectively). In the classic 5-HT2B test, EGIS-7625 produced a concentration-related parallel rightward shift in the concentration-response relationship for the 5-HT-induced smooth muscle constriction in rat stomach fundus strips with a pA2 of 9.4. On the other hand, EGIS-7625 was a weak competitive antagonist at 5-HT2A receptors as it shifted 5-HT-induced concentration-response curves to the right at high concentrations (pA2 = 6.7) in rabbit pulmonary artery strips. The m-chlorophenylpiperazine-induced hypomotility and hypophagia was only partially attenuated by EGIS-7625 even at a dose of 30 mg/kg i.p. while mianserin, a non-selective 5-HT antagonist was almost fully effective in these tests at 3 mg/kg i.p., suggesting weak antagonistic effect of EGIS-7625 at neuronal 5-HT2C receptors, in vivo. In conclusion, EGIS-7625 is a potent, selective and competitive 5-HT2B antagonist that seems to be a good research tool for the separation of the functional roles of vascular 5-HT2A and 5-HT2B receptors.


Journal of Fluorine Chemistry | 1996

Synthesis of α-(trifluoromethyl)phenylacetonitrile. Anomalous reactions of α-tosyloxy-α-(trifluoromethyl)phenylacetonitrile with sodium borohydride

Gábor Németh; László Poszácz; Daniel Bozsing; Gyula Simig

Abstract The hitherto unknown α-(trifluoromethyl)phenylacetonitrile has been synthesized by reduction of the cyanohydrin of α,α,α-trifluoroacetophenone. Sodium borohydride reduction of the corresponding cyanohydrin tosylate resulted in reductive decyanation in dimethyl sulphoxide and in reduction of the nitrile group in t-butanol.


Bioorganic & Medicinal Chemistry Letters | 2002

Synthesis and evaluation of 5-HT2A and 5-HT2C receptor binding affinities of novel pyrimidine derivatives

Daniel Bozsing; Ildikó Rátzné Simonek; Gyula Simig; Ivan Jakoczi; Istvan Gacsalyi; Gyoergy Levay; Károly Tihanyi; Eva Schmidt

In an effort to find potential anxiolytic and/or antipsychotic agents with selective 5-HT(2C) affinity a series of new pyrimidine derivatives was prepared and the binding affinities for 5-HT(2A) and 5-HT(2C) receptors were determined.


Archive | 2001

A process for the preparation of quetiapine and intermediates therefor

Daniel Bozsing; Lax Györgyi Koványiné; Gyula Simig; Györgyné Rákóczy; Peter Tompe; György Krasznai; Donáth Györgyi Vereczkeyné; Kalman Nagy


Archive | 1998

Process for the preparation of a dihydropyridine derivative

Daniel Bozsing; Gyorgyi Kovanyi; Gyula Simig; György Krasznai; Gabor Blasko; Peter Tompe; Kalman Nagy; Györgyi Donáth Vereczkey; Gabor Nemei; Norbert Nemeth


Archive | 1998

A process and intermediate compounds for the preparation of amlodipine benzene sulphonate

Gábor Dr. Blask; Daniel Bozsing; Györgyi Lax Dr. Koványi; György Krasznai; Kalman Nagy; Gábor Német; Norbert Nemeth; Gyula Simig; Peter Tompe; Györgyi Donáth Vereczkey


Archive | 1982

Quinoxaline-2-yl ethenyl ketones

Pal Benko; Daniel Bozsing; Janos Gundel; Karoly Magyar


Archive | 2000

Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance

Ildikó Rátzné Simonek; Daniel Bozsing; Gábor Németh; Gyula Simig; László Poszávácz; Ivan Jakoczi; György Lévay; Istvan Gacsalyi; Károly Tihanyi; Janos Wellmann; Andras Egyed


Archive | 1997

Novel piperazine or homopiperazine derivatives, pharmaceutical compositions containing the same and a process for their preparation

Simonek Ildiko Ratzne; Daniel Bozsing; Ivan Jakoczi; Lax Györgyi Koványiné; Gabor Blasko; Gyula Simig; Istvan Gacsalyi; Eva Schmidt; Kovacs Aniko Miklosne; Kiszelly Eniko^' Szirtné; Gábor Szénási; István Gyertyán; Andras Egyed; Károly Tihanyi

Collaboration


Dive into the Daniel Bozsing's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge